

Research Article: New Research | Development

## The IgCAM BT-IgSF (IgSF11) is essential for connexin43-mediated astrocyte-astrocyte coupling in mice

<https://doi.org/10.1523/ENEURO.0283-23.2024>

Received: 6 July 2023

Revised: 19 January 2024

Accepted: 24 January 2024

Copyright © 2024 Pelz et al.

This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](#), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

---

*This Early Release article has been peer reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data.*

**Alerts:** Sign up at [www.eneuro.org/alerts](http://www.eneuro.org/alerts) to receive customized email alerts when the fully formatted version of this article is published.

1 **1. Manuscript Title: The IgCAM BT-IgSF (IgSF11) is essential for connexin43-mediated astrocyte-**  
2 **astrocyte coupling in mice**

3  
4 **2. Abbreviated Title:** BT-IgSF controls astrocyte-astrocyte coupling

5  
6 **3. List all Author Names and Affiliations:**

7 Laura Pelz<sup>1</sup>, Laura Dossou<sup>1</sup>, Nine Kompier<sup>1</sup>, René Jüttner<sup>1</sup>, Gabrielle Siemonsmeier<sup>1</sup>, Niklas Meyer<sup>1</sup>, Elijah  
8 D. Lowenstein<sup>1</sup>, Ines Lahmann<sup>1</sup>, Helmut Kettenmann<sup>1,2</sup>, Carmen Birchmeier<sup>1,3</sup>, and Fritz G. Rathjen<sup>1</sup>

9 1) Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Str. 10, DE-13092 Berlin, Germany

10 2) Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences  
11 Shenzhen, China

12 3) NeuroCure Cluster of Excellence, Charité Universitätsmedizin Berlin, Corporate Member of Freie  
13 Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

14  
15 **4. Author Contributions:** LP, LD, NK, GS, NM, EL, IL, RJ and FGR performed experiments, RJ, HK, CB and  
16 FGR evaluated data. FGR drafted and wrote the final version of the manuscript.

17  
18 **5. Correspondence should be addressed to**

19 Fritz G. Rathjen, Max-Delbrück-Center, Robert-Rössle-Str. 10, DE-13092 Berlin, Germany, ([rathjen@mdc-](mailto:rathjen@mdc-berlin.de)  
20 [berlin.de](mailto:rathjen@mdc-berlin.de))

21 **6. Number of Figures: 7, extended Figures 4**

22 **7. Number of Tables: 1**

23 **8. Number of Multimedia: 0**

24 **9. Number of words for Abstract: 187**

25 **10. Number of words for Significance Statement: 70**

26 **11. Number of words for Introduction: 783**

27 **12. Number of words for Discussion: 1843**

28  
29 **13. Acknowledgements**

30 We thank Mechthild Henning for technical assistance and Karola Bach, Stefanie Rode and Petra Stallerow for  
31 mouse breeding. We thank Dr. Thomas Müller (MDC) with the help in assembling Figure 4. We thank Dr  
32 Christopher Patzke (University of Notre Dame, USA) for the critical reading of the manuscript. FGR is an  
33 emeritus professor at the MDC. We acknowledge the advice of Dr. Frank Konietzschke (Institut für Biometrie  
34 und Klinische Epidemiologie Charité, Berlin, Germany) on the statistical evaluations of our data.

35 **Present addresses:** Laura Pelz: National Center for Tumor Diseases (NCT) Heidelberg and the German Cancer  
36 Research Center (DKFZ), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.

37 Laura Dossou: Pfizer Pharma GmbH, Linkstraße 10, 10785 Berlin, Germany

38 Gabrielle Siemonsmeier: McGill University, Integrated Program in Neuroscience, Irving Ludmer Building, 1033  
39 Pine Avenue West, Montréal, Québec H3A 1A1, Canada

40 Niklas Meyer: Department of Neurology with Institute of Translational Neurology, University of Münster, DE-  
41 48149 Münster, Germany.

42 Elijah D. Lowenstein: Department of Medicine, Division of Endocrinology, Diabetes and Metabolism. Beth Israel  
43 Deaconess Medical Center and Harvard Medical School, Boston, MA 02115, USA.

44 **14. Conflict of Interest**

45 Authors report no conflict of interest

46  
47 **Funding sources** This work was supported in part by funds from the Deutsche Forschungsgemeinschaft SFB 665  
48 to FGR, KE329/28 to HK, GO865/13-1 to Dr Michael Gotthardt (MDC), EXC-2049 – 39068808 (Germany's  
49 Excellence Strategy) to CB and the MDC.

50

51 **The IgCAM BT-IgSF (IgSF11) is essential for connexin43-mediated astrocyte-astrocyte**  
52 **coupling in mice.**

53

eNeuro Accepted Manuscript

54 **Abstract**

55           The type I transmembrane protein BT-IgSF is predominantly localized in the brain and  
56 testes. It belongs to the CAR subgroup of Ig cell adhesion proteins, that are hypothesized to  
57 regulate connexin expression or localization. Here, we studied the putative link between BT-  
58 IgSF and connexins in astrocytes, ependymal cells and neurons of the mouse. Global knockout  
59 of BT-IgSF caused an increase in the clustering of connexin43 (Gja1), but not of connexin30  
60 (Gjb6), on astrocytes and ependymal cells. Additionally, knockout animals displayed reduced  
61 expression levels of connexin43 protein in the cortex and hippocampus. Importantly, analysis  
62 of biocytin spread in hippocampal or cortical slices from mature mice of either sex revealed a  
63 decrease in astrocytic cell-cell coupling in the absence of BT-IgSF. Blocking either protein  
64 biosynthesis or proteolysis showed that the lysosomal pathway increased connexin43  
65 degradation in astrocytes. Localization of connexin43 in subcellular compartments was not  
66 impaired in astrocytes of BT-IgSF mutants. In contrast to connexin43 the localization and  
67 expression of connexin36 (Gjd2) on neurons was not affected by the absence of BT-IgSF.  
68 Overall, our data indicate that the IgCAM BT-IgSF is essential for correct gap junction-  
69 mediated astrocyte-to-astrocyte cell communication.

70

71

72 **Significance Statement**

73 Astrocytes regulate a variety of physiological processes in the developing and adult brain that  
74 are essential for proper brain function. Astrocytes form extensive networks in the brain and  
75 communicate via gap junctions. Disruptions of gap junction coupling are found in several  
76 diseases such as neurodegeneration or epilepsy. Here, we demonstrate that the cell adhesion  
77 protein BT-IgSF is essential for gap junction mediated coupling between astrocytes in the  
78 cortex and hippocampus.

79

80 **Key words:** IgCAM, BT-IgSF, gap junctions, connexin43, astrocyte-astrocyte coupling

eNeuro Accepted Manuscript

## 81 **Introduction**

82

83 BT-IgSF (brain- and testis-specific Ig superfamily protein, also known as IgSF11) is a  
84 cell adhesion protein belonging to a small subgroup of IgCAMs consisting of CAR  
85 (coxsackievirus and adenovirus receptor), ESAM (endothelial cell-selective adhesion  
86 molecule) and CLMP (CAR-like membrane protein). The group shares a similar overall domain  
87 organization with an N-terminal V-type and a C2-type Ig domain and a highly related amino  
88 acid sequence (Owczarek et al., 2023; Raschperger et al., 2004; Rathjen, 2020; Xie et al., 2021).  
89 Initially BT-IgSF was described as a novel IgSF member that was preferentially expressed in  
90 the brain and testis (Suzu et al., 2002). Independently of this report BT-IgSF was also found to  
91 be up-regulated in intestinal-type gastric cancers and termed IgSF11 (Katoh and Katoh, 2003).  
92 Moreover, it was also termed V-set and Immunoglobulin domain containing 3, abbreviated  
93 VSIG-3, due to its binding to VISTA (Wang et al., 2019). The BT-IgSF gene is located on  
94 chromosome 3 in humans and chromosome 16 in mice. The cytoplasmic segment of BT-IgSF  
95 contains a PDZ-binding motif at its C-terminus that interacts with the scaffolding protein  
96 PSD95 (Jang et al., 2015). Adhesion assays with heterologous cells showed that BT-IgSF  
97 promotes homotypic cell binding (Eom et al., 2012; Harada et al., 2005).

98 So far, the function of BT-IgSF (IgSF11) has been studied in neurons, Sertoli and germ  
99 cells of the testes, during osteoclast differentiation and in the organization of pigment cells in  
100 fish (Ahi and Sefc, 2017; Chen et al., 2021; Eom et al., 2012; Hayano et al., 2021; Jang et al.,  
101 2015; G. M. Kim et al., 2023; H. Kim et al., 2023; Kim et al., 2020; Pelz et al., 2017; Singh and  
102 Nusslein-Volhard, 2015). Knockdown studies using cultured mouse hippocampal neurons  
103 indicated that BT-IgSF is implicated in synaptic transmission through a tripartite interaction  
104 with PSD95 and AMPA receptors (Jang et al., 2015). Consequently, global BT-IgSF-deficient  
105 mice displayed a moderately decreased excitatory synaptic strength in the dentate gyrus and  
106 long-term potentiation in hippocampal CA1 neurons and behavioral deficits (Jang et al., 2015;

107 Montag et al., 2023). In another study analyzing neurons BT-IgSF (IgSF11) was found to  
108 regulate chandelier cell axon innervation of pyramidal neuron initial axon segments (Hayano  
109 et al., 2021).

110 In the murine testis BT-IgSF is expressed in Sertoli cells at the blood-testes barrier, a  
111 structure that opens and closes to allow the passage of germ cells. In a global knockout, the  
112 absence of BT-IgSF causes a malfunction of the blood-testes-barrier leading to male infertility  
113 due to the mislocalization of connexin43. Connexin43 was found throughout the seminiferous  
114 epithelium instead of being restricted to the blood-testes barrier as it is in wildtype animals.  
115 Therefore BT-IgSF might regulate the localization or activity of connexin43 in Sertoli cells  
116 (Pelz et al., 2017). In line with this finding connexin43 was found to play an essential role in  
117 tight junction reassembly at the blood-testes barrier during its restructuring processes (Li et al.,  
118 2010). A critical role of BT-IgSF in regulating the organization of pigment cells into stripes  
119 along the dorso-ventral or anterior-posterior body axes was observed in zebrafish and  
120 *Neolamprologus meeli* (Ahi and Sefc, 2017; Eom et al., 2012; Singh and Nusslein-Volhard,  
121 2015). Similar irregular patterns of chromatophores were described in zebrafish with mutations  
122 in connexin 41.8 and connexin39.4, suggesting a functional link between BT-IgSF and  
123 connexins. This link might also be anticipated from the mislocalization of connexin43 in Sertoli  
124 cells of BT-IgSF knockout mice (Haffter et al., 1996; Irion et al., 2014; Pelz et al., 2017;  
125 Watanabe et al., 2006; Watanabe and Kondo, 2012). Together, these data suggest an essential  
126 function of BT-IgSF in regulating the localization or activity of connexins as shown for other  
127 members of the CAR subgroup.

128 To further investigate the functional interaction between BT-IgSF and connexin43, we  
129 investigated its role in the brain on glial cells. Here, we show that BT-IgSF is strongly localized  
130 on the surface of astrocytes and ependymal cells in addition to its previously described neuronal  
131 expression (Higashine et al., 2018; Jang et al., 2015; Suzu et al., 2002). In the absence of BT-  
132 IgSF in a global mouse knockout we observed that the localization of connexin43 on astrocytes

133 and ependymal cells was aberrantly clustered. Additionally, we uncovered a severe reduction  
134 in connexin43 on astrocytes at the protein level. Consequently, dye-loading experiments  
135 revealed reduced diffusion within the astrocytic network in the hippocampus as well as in the  
136 cortex of mutant mice. We discuss these findings in the context of the function of the related  
137 proteins CLMP and CAR which also affect the expression and localization of connexin43 and  
138 45 in smooth muscle cells of the intestine and in cardiomyocytes, respectively (Langhorst et al.,  
139 2018; Lim et al., 2008; Lisewski et al., 2008; Matthaeus et al., 2023; Rathjen, 2020).

140

141

eNeuro Accepted Manuscript



## 142 **Material and Methods**

143

### 144 **Mice**

145           The global knockout of BT-IgSF (B6-IgSF11<sup>tm1e(KOMP)Wtsi</sup>/FGR) and its genotyping has  
146 been described elsewhere (Pelz et al., 2017). Breeding was either from tg/wt to tg/wt or tg/tg  
147 (female) to wt/tg (male). Heterozygous BT-IgSF mice did not differ from wt/wt mice (Pelz et  
148 al., 2017). Cx36-deficient mice (B6.129P2-Gjd2tm1Kwi/Cnrm; EM:00326) were obtained  
149 from the European Mouse Mutant Archive (EMMA) and genotyped as described (Güldenagel  
150 et al., 2001). Animals were housed on a 12/12 h light/dark cycle with free access to food and  
151 water. The animal procedures were performed according to the guidelines from directive  
152 2010/63/EU of the European Parliament on the protection of animals used for scientific  
153 purposes. All experiments were approved by the local authorities (LaGeSO) (numbers  
154 T0313/97, X 9007/16, X9008/20, O 0038/08 and H0027/20). Wildtype littermates served as  
155 controls.

156

### 157 **Cell culture, antibodies and immunocytochemistry**

158           Hippocampal cells were prepared from postnatal day 2 or 3 mice and cultured on poly-  
159 D-lysine coated coverslips in 24-well plates at a density of  $7.5 \times 10^4$  cells/ml in Neurobasal  
160 (Invitrogen) supplemented with B27 (Invitrogen) and 10% FCS (Gibco) for 10 days. Every  
161 third day half of the culture medium was removed and replaced by Neurobasal/B27 without  
162 FCS. Glial cells from postnatal day 2/3 cortices or hippocampi were prepared according to  
163 standard procedures and were maintained in DMEM supplemented with 10% FCS and  
164 penicillin/streptomycin in 75 cm<sup>2</sup> flasks until confluent (McCarthy and de Vellis, 1980). Then,  
165 astrocytes were detached by trypsin/EDTA treatment and further grown in multiple 24 well  
166 cluster (200 000 cells per well) for cycloheximide or chloroquine treatment (see below) or on

167 poly-D-lysine coated coverslips (20 000 cells per 12 mm diameter coverslip) for staining with  
168 antibodies to specific intracellular compartments (see below). Cells of each 24 well cluster were  
169 extracted as described below and equal amounts were analyzed by Western blotting (see below).  
170 For immunocytochemistry cells were fixed in 4% paraformaldehyde/PBS for 10 minutes,  
171 washed with PBS/1% BSA. For staining of cryosections (thickness 12-16  $\mu\text{m}$ ) by indirect  
172 immunofluorescence, adult mice were transcardially perfused with 50 ml PBS followed by 50  
173 ml 4% paraformaldehyde. Brains were post fixed for 5 hours and then transferred into 15%  
174 followed by 30% (w/v) sucrose in PBS to obtain cryoprotection. Primary and fluorophore-  
175 conjugated secondary antibodies were applied in blocking solution (5% goat serum, 1% BSA,  
176 0.1% Triton X-100 in PBS). Mouse monoclonal antibodies were incubated on sections using  
177 the MOM immunodetection kit from Vector Laboratories (BMK-2202). Sections or monolayer  
178 cultures were counterstained with the nuclear stain DAPI at 1  $\mu\text{g}/\text{ml}$ . For antibodies see table  
179 1.

180 Microscopic images were obtained at room temperature by confocal imaging using a  
181 Carl Zeiss LSM 700 Laser Scanning Microscope equipped with ZEN 2011 software and the  
182 following lenses: a Plan-Neofluar 20x/0.30 NA objective, a Plan-Achromat 40x/1.3 Oil, a Plan-  
183 Achromat 63x/1.40 NA oil objective or a Plan Apochrome 100x/1.40 oil objective (all from  
184 Carl Zeiss MicroImaging, GmbH). Figures were assembled using Illustrator CS5 (Adobe).

185 To quantify connexin43 clusters confocal images were taken with a 63x objective from  
186 cryosections and a 100x objective for cultured astrocytes. Quantification of connexin43 clusters  
187 was done by Fiji software setting threshold to RenyiEntropy routine; clusters were accepted  
188 between 0.05 and 1.00  $\mu\text{m}^2$  (2-40 pixels). Primary branches of astrocytes and the density of  
189 astrocytes were counted from hippocampal slices stained by anti-GFAP and DAPI positive  
190 cells.

191 Analysis of localizations or co-localizations of connexin43 to intracellular compartments were  
192 done with antibodies to  $\gamma$ -adaptn, LAMP-1, ZO-1, GM130, to phalloidin-Alexa594 (6.6  $\mu\text{M}$ ;

193 1:500; Thermo Scientific #A12381) or to BT-IgSF (Rb96) (see table 1) on 4%  
194 paraformaldehyde/PBS-fixed (5 minutes on ice) on wildtype and knockout astrocyte cultures.  
195 Assessment of cell surface localization of connexin43 cluster on knockout astrocytes was done  
196 by life staining of astrocytes with WGA-488 (1  $\mu$ g/ml; ThermoFisher Scientific W11261) at 4<sup>0</sup>  
197 C for 45 minutes followed by washing, PFA fixation and solubilization with 0.1% Triton-X100.  
198 Then rabbit antibodies to connexin43 were added as described above. Images were obtained by  
199 confocal microscopy using the 100x oil objective mentioned above and were analyzed using  
200 Fiji/Image J. Calculation of the Pearson correlation was determined by Coloc 2 derived  
201 intensity-based correlation analysis from regions of interest around connexin43 clusters (10  $\mu$ m  
202 circles). Costes threshold regression was applied and Pearson's R value (P) above threshold  
203 was used, data were accepted with an Costes p-value >0.95. Mann-Whitney U-test (GraphPad  
204 Prism 6.07) was used to compare wildtype with knockout values.

#### 205 **Generation of a connexin 36 fusion protein and polyclonal antibodies to connexin36.**

206 Since several commercial anti-connexin36 antibodies were of limited use in our hands  
207 we generated polyclonal anti-mouse connexin36 antibodies in rabbits using a fusion protein  
208 that comprised the second cytoplasmic segment of mouse connexin36 (amino acid residues 99  
209 – 197) attached to a histidine stretch. The cDNA of this segment was synthesized by Invitrogen  
210 and cloned into plasmid pMA-RQ and further subcloned into the bacterial expression vector  
211 pET-14b (Novagen/EMD Millipore). The protein was expressed in B121 bacteria with the  
212 addition of IPTG to a final concentration of 1 mM. Bacteria were harvested by centrifugation  
213 and frozen at -80°C. Bacterial pellets were resuspended in ice-cold lysis buffer containing 2 M  
214 Urea, 50 mM Tris, 150 mM NaCl, pH 7.4, supplemented with protease blockers (aprotinin,  
215 PMSF, leupeptin, pepstatin). Unsolubilized material was removed by centrifugation and the  
216 supernatant was precipitated by ammonium sulfate (50% saturation). The pellet was dialyzed  
217 against 10 mM Tris, pH 11 and run over an anion exchange column (DE52 Whatman). The

218 unbound fraction was applied to an NTA column (Qiagen), washed with PBS followed by 20  
219 mM imidazole and bound protein was eluted by 200mM imidazole. Purity was analyzed by  
220 15% SDS PAGE. Rabbits were injected with 100 µg protein in Freund's adjuvant at fortnightly  
221 intervals. The IgG fraction was obtained by protein A affinity chromatography (GE Health  
222 Care) and further purified by affinity chromatography on an affinity column containing the  
223 above mentioned connexin36 segment protein coupled to CNBr-activated Sepharose (14 mg to  
224 2.5 g Sepharose 4B; GE Healthcare). The specificity of the affinity purified antibodies was  
225 tested on tissue extracts and cryostat sections (12 µm thick, mildly fixed with 1%  
226 paraformaldehyde/PBS for 1 minute on ice) from wildtype or connexin36-deficient mice (see  
227 Figure 7).

228

### 229 **Biochemical methods**

230 To obtain a crude membrane fraction from tissues of BT-IgSF knockout or wildtype  
231 mice of different ages (as indicated in the Figure legends), hippocampi or cortices were  
232 homogenized in 0.34 M sucrose supplemented with protease blockers [aprotinin (20 U/µl),  
233 leupeptin (5 mM), pepstatin (5mM), PMSF (1mM)]. Nuclei were pelleted at 200xg for 10  
234 minutes and the resulting supernatant was centrifuged at 100 000xg for 10 minutes to obtain a  
235 crude membrane pellet and cytoplasmic fraction in the supernatant. Membranes were stripped  
236 with 0.1 M diethylamine (pH11.5), supplemented with protease blockers to remove peripheral  
237 membrane proteins. The membrane fraction was first solubilized in 1% Triton-X100 and un-  
238 solubilized material was removed by centrifugation. The pellet was then solved in 1% SDS in  
239 PBS supplemented with protease blockers and un-solubilized material was again removed by  
240 centrifugation (Musil and Goodenough, 1991). Protein concentrations were determined using  
241 the Bradford assay (Bio-Rad #500-0006) and spectrophotometric measurements. Equal  
242 amounts of proteins were loaded on SDS-PAGE for Western blotting which was controlled by  
243 Ponceau protein stain and housekeeping proteins such as GAPDH, heavy chain of clathrin, or

244  $\alpha$ -tubulin. Depending on the tissue or antibody, 10, 15 or 20  $\mu$ g of protein was loaded per lane.  
245 Blots to identify BT-IgSF in cells or tissues SDS-PAGE was run without reducing agents. For  
246 the calculation of the molecular mass of connexin36 in neural tissues the following molecular  
247 mass standards were used (in kDa): Conalbumin, 76; BSA, 66, actin, 43; GAPDH, 36 and  
248 carbonic anhydrase, 31.

249 Cycloheximide chase experiments (100  $\mu$ g/ml, Sigma, C-7698, dissolved in DMSO and  
250 diluted 1:500 in the incubation medium) were done with wildtype and BT-IgSF knockout  
251 astrocytes cultures for times indicated in the Figure 3G to H. 200 000 cells were grown in 24  
252 well clusters in DMEM/10% FCS and washed two times with DMEM without FCS before the  
253 addition of cycloheximide. Chloroquine experiments (100  $\mu$ M; Sigma C6628, dissolved in  
254 PBS) to inhibit lysosomal degradation were done with wildtype and BT-IgSF knockout  
255 astrocytes cultures for 4 hours in DMEM without FCS (Schrezenmeier and Dörner, 2020; Wu  
256 et al., 2016). Treatment of wildtype astrocytes with tumor necrosis factor- $\alpha$  (1 ng/ml; Sigma  
257 T5944) or interferon- $\gamma$  (10 ng/ml; Sigma I17001) were done in DMEM without FCS for 24  
258 hours. In these blocking experiments cells were lysed in TBS (pH 7.4) with 1% SDS and 1 mM  
259 EDTA supplemented with protease blockers and boiled in SDS-PAGE sample buffer. Equal  
260 amounts of protein were loaded on 10% SDS PAGE, blotted and analyzed with rabbit anti-  
261 connexin43 or rabbit 96 to BT-IgSF. Equal loading was controlled by Ponceau protein stain  
262 and mAb to GAPDH. Quantification of connexin43 bands was done using Image Lab software  
263 (BioRad) and analyzed by Mann-Whitney-test and Two-Way ANOVA (GraphPad Prism 6.07).  
264 Total connexin43 expression was derived from the sum of connexin43 bands P0, P1 and P2  
265 (bands P1 and P2 correspond to phosphorylated connexin43).

266

### 267 **RNAscope on hippocampus sections**

268 *In situ* fluorescent hybridization was performed using the RNAscope Multiplex  
269 Fluorescent Assay from ACDbio according to the manufacturer's instructions (Wang et al.,

270 2012). Briefly, PFA-fixed hippocampus or midbrain sections of 20  $\mu\text{m}$  thickness were obtained  
271 from P20 or P10 wildtype mice, respectively, and stored at  $-80^{\circ}\text{C}$  until use. Sections were  
272 thawed at  $37^{\circ}\text{C}$  for 10 minutes and post-fixed in 4% PFA in PBS for 15 minutes before washing  
273 in PBS and continuing with the manufacturer's instructions. Protease treatment was performed  
274 using Protease IV. RNAscope probes against BT-IgSF (C1 - 451131), GFAP (C2 - 313211),  
275 vGlut1 (C2 - 416631) and GAD65/67 (Gad1: C2 - 400951; Gad2: C2 - 439371) were used.

276

### 277 **Dye coupling in acute brain slices**

278 To characterize the tracer spread within coupled astrocytic networks acute brain slices  
279 containing the hippocampus or the cortex were prepared from 8–10-week-old knockout or  
280 littermate controls of either sex as described previously (Maglione et al., 2010). In brief, mice  
281 were sacrificed by cervical dislocation, decapitated and their brains carefully removed and  
282 mounted in a chamber with ice-cold bicarbonate-buffered artificial cerebrospinal fluid (ACSF),  
283 composed of (in mM): NaCl 134; KCl 2.5;  $\text{MgCl}_2$  1.3;  $\text{CaCl}_2$  2;  $\text{K}_2\text{HPO}_4$  1.25;  $\text{NaHCO}_3$  26; D-  
284 glucose 10; pH 7.4. The buffer solution was continuously gassed with carbogen (95%  $\text{O}_2$ , 5%  
285  $\text{CO}_2$ ). Coronal slices of 250  $\mu\text{m}$  were prepared at  $4^{\circ}\text{C}$  using a vibratome (HM 650 V, Microm  
286 International GmbH, Walldorf, Germany), and stored in ACSF at room temperature ( $21$ – $25^{\circ}\text{C}$ )  
287 for up to 5 hours.

288 Before dye filling, slices were incubated for 20 minutes in  $1\mu\text{M}$  sulforhodamine 101  
289 (SR-101) at  $35^{\circ}\text{C}$  to label astrocytes. Astrocytes were identified by their SR-101 fluorescence  
290 at excitation and emission wavelengths of 555 and  $585 \pm 10$  nm, respectively, using a 60x  
291 water-immersion objective (Olympus, Hamburg, Germany). For recording and for dye loading,  
292 a patch pipette (pulled from borosilicate glass, 1.5 mm outside diameter, 0.315 mm wall  
293 thickness) was filled with a solution containing 30 mM KCl, 1 mM  $\text{MgCl}_2$ , 0.5 mM  $\text{CaCl}_2$ , 100  
294 mM potassium-gluconate, 10 mM HEPES, 5 mM EGTA, 0.5% biocytin (Sigma-Aldrich) and 3  
295 mM  $\text{Na}_2\text{ATP}$ , pH 7.3. Lucifer Yellow (10  $\mu\text{g}/\text{ml}$ ; Sigma-Aldrich) was added to the pipette

296 solution and intracellular access of the solution was confirmed by excitation at 495 nm and  
297 visualization at an emission wavelength of  $510 \pm 10$  nm. The pipette resistance ranged from 5  
298 – 8 M $\Omega$ . Cells were passively dialyzed via the patch pipette for 20 min. In order to confirm cell  
299 identity and vitality, membrane currents were recorded with a series of de- and hyperpolarizing  
300 voltage steps (10 mV each, filtered at 2.9 kHz) from a holding potential of -70 mV ranging  
301 from -160 to +50 mV for 50 ms), using an EPC 10 patch-clamp amplifier and TIDA 5.25  
302 software (HEKA Elektronik, Lambrecht, Germany), as described previously (Richter et al.,  
303 2014). Capacitive transients from the pipette were compensated online via the patch clamp  
304 amplifier ( $C_{fast}$ ) whereas membrane capacity and series resistance ( $C_{slow}$ ) were not compensated.  
305 The calculated liquid junction potential of the used intra cellular solutions was – 8.858 mV  
306 using Patchers Power Tools (Mendez & Würriehausen, Göttingen, Germany) and Igor Pro 7  
307 software (Wavemetrics, Portland, OR, USA). The calculated reversal potentials of astrocytes  
308 were corrected for the liquid junction potential. Only cells whose series resistance was not  
309 higher than 125 % at the end of the dialysis phase compared to the beginning of the recording  
310 were taken into account for the following immunohistochemical experiments and the  
311 calculation of the membrane properties. After dye loading and patch-clamp recording, the  
312 pipette was carefully removed from the cell in order to disrupt the patch.

313 Slices were subsequently fixed in a solution of 4% paraformaldehyde in 0.1 M  
314 phosphate buffered saline (pH 7.4) overnight at 4°C. After fixation, slices were incubated in a  
315 solution containing 2% Triton-X100, 2% BSA and 5% normal donkey serum in Tris-buffered  
316 saline at pH 7.4 for 2 h at room temperature to permeabilize and to block nonspecific binding  
317 of the primary antibodies. Biotin-filled networks were visualized with Cy3-conjugated  
318 streptavidin (1:200; Jackson ImmunoResearch, Hamburg, Germany). In addition, rabbit anti-  
319 BT-IgSF (Rb95) and guinea pig anti-GFAP antibodies were applied to label BT-IgSF and  
320 astrocytes, respectively. The floating slices were incubated with primary antibodies for 48 h at  
321 4°C followed by secondary antibodies and DAPI. For additional antibodies see table 1.

322 Slices were rinsed and mounted with Aqua Poly/Mount (Polysciences Inc., Washington,  
323 USA). Images were acquired by a Leica DM TCS SPE confocal microscope (HC APO  
324 20x/0.75; Leica, Solms, Germany) with Leica software (LCS Lite or LAS AF Lite,  
325 respectively). Step size between z-planes in the confocal stacks was about 1  $\mu\text{m}$ , but the number  
326 of imaged planes in each stack varied from slice to slice. Images were analyzed by Fiji/Image  
327 J software, using the cell counter plugin and z-axis projection functions.

328

### 329 **Statistics**

330 Significance of data were tested using nested t-test, Mann-Whitney-test, unpaired t-test  
331 with Welch correction or One-Way ANOVA using GraphPad Prism software (version 6.07  
332 and version 10.1.2) after excluding outlier using the outlier tests (ROUT, Q=1%). Normality  
333 was tested using the D'Agostino & Pearson omnibus normality test or Shapiro-Wilk normality  
334 test.

335

336

337

338



339 **Results**

340 **Absence of BT-IgSF disrupts the expression and localization of connexin43 in the**  
341 **hippocampus and on cultured astrocytes**

342

343 BT-IgSF was first described as an IgSF member that was preferentially expressed in the  
344 brain and testis (Suzu et al., 2002). BT-IgSF and related proteins of the CAR family of adhesion  
345 proteins have been proposed to modulate the localization of connexins (Rathjen, 2020). We  
346 tested whether the absence of BT-IgSF affects the localization of connexin43 expression on  
347 astrocytes as it does on Sertoli cells in the testes (Pelz et al., 2017). In the mature brain  
348 connexin43 is expressed by astrocytes and ependymal cells, but not by neurons. Connexin30  
349 and connexin26 have also been detected in adult astrocytes, albeit at lower levels (Dermietzel  
350 et al., 1989; Nagy et al., 2004). Hippocampal sections as well as astrocyte monolayer cultures  
351 were labeled with rabbit anti-connexin43 antibodies. Microscopic images of hippocampal  
352 sections revealed an altered localization of connexin43 in BT-IgSF knockout tissue (Figure 1A  
353 and B). In the molecular layer of knockout hippocampal tissue, a pronounced decrease in the  
354 number of connexin43 spots (31% of the wildtype), accompanied by a marked increase in the  
355 connexin43 spot size (average of 0.19 to 0.5  $\mu\text{m}^2$  in wildtype and BT-IgSF<sup>-/-</sup> mice,  
356 respectively) was observed in high power magnifications (Figure 1C, E and F). Similar  
357 observations on the clustering and number of connexin43 spots were made on cultured  
358 astrocytes, suggesting that BT-IgSF might control connexin43 localization even in the absence  
359 of neurons (Figure 1D, H and I). Analysis of the distribution of the number of counts versus  
360 cluster size further highlights the difference between wildtype and BT-IgSF knockouts (Figure  
361 1G and J). Taken together, our data indicate that the absence of BT-IgSF decreases the number  
362 of connexin43 spots but increases their clustering in astrocytes.

363 We further investigated BT-IgSF expression on neural cells by immunocytochemistry  
364 of hippocampal cultures and brain sections. In monolayer cultures prepared from newborn

365 hippocampal tissue BT-IgSF was primarily localized on the surface of GFAP-positive  
366 astrocytes (Figure 2A and B and Extended Figure 2-1 on the specificity of the anti-BT-IgSF  
367 antibody) and was not or only weakly detected on MAP2-positive dendrites (Figure 2C).  
368 However, single molecule fluorescent *in situ* hybridization (RNAscope) experiments indicated  
369 that neurons express detectable amounts of *Bt-igsf* mRNA (Extended Figure 2-2). Similarly,  
370 *Bt-igsf* mRNA was found in GFAP-positive cells in sections of the molecular layer of the  
371 hippocampus (Figure 2E and F), which is further supported by immunohistochemistry using  
372 polyclonal antibodies to the extracellular region of BT-IgSF (Figure 2D). BT-IgSF protein  
373 expression increases as the brain matures postnatally and effective solubilization from crude  
374 membrane fractions requires ionic detergents such as SDS (Figure 2G - J).

375 To analyze connexin43 in Western blots, hippocampus and cortex crude membrane  
376 fractions from wildtypes and mutants were prepared. Membranes were first treated by Triton-  
377 X100 containing buffer followed by SDS of the pellet to separate soluble (primarily non-  
378 junctional) from insoluble (mainly junctional) connexin43. Significant decreases in connexin43  
379 levels in both Triton-X100- and SDS-containing fractions were found in the mutant (Figure 3A  
380 and B). In contrast to connexin43, connexin30, which is also implicated in the extensive  
381 network organization of astrocytes and which can also form gap junction channels together with  
382 connexin43 (Nagy et al., 2004; Willecke et al., 2002), is not reduced nor is its overall  
383 localization changed in the hippocampus in the absence of BT-IgSF (Figure 3C and D). No  
384 changes in GFAP protein level were detected (Figure 3E and F) in the hippocampus of BT-  
385 IgSF mutants. This indicated that the reduction in connexin43 levels was not caused by a  
386 decrease in GFAP i.e., a decrease in the number of astrocytes (see also Figure 5K to N).

387 Connexin43 has a high turnover rate. Therefore, the reduced expression of connexin43  
388 might be caused by decreased biosynthesis, increased degradation by multiple pathways or by  
389 trafficking deficits from the cytoplasm to the plasma membrane (Falk et al., 2016; Laird and  
390 Lampe, 2018). We measured connexin43 protein levels using Western blots in a chase

391 experiment after adding the protein synthesis blocker cycloheximide in wildtype and BT-IgSF  
392 knockout astrocyte cultures. In both cultures, the amount of connexin43 protein significantly  
393 decreased in the presence of cycloheximide. After 180 minutes of incubation with  
394 cycloheximide the level of connexin43 protein decreased to 60 percent of baseline in both  
395 genotypes (Figure 3G and H). However, no differences between wildtype and knockout cultures  
396 were detected at different incubation periods. Linear regression analysis revealed that 50% of  
397 connexin43 would be present after 210.0 minutes and 235.1 minutes in wildtype and knockout  
398 astrocytes, respectively ( $p=0.8869$ , unpaired t-test with Welch's correction). Interestingly, the  
399 addition of the lysosome inhibitor chloroquine for 4 hours led to an increase in connexin43  
400 protein in knockout cultures (to 126% on average) but only sparsely in control cultures (105%)  
401 (Figure 3I and J) as the change in the latter did not reach statistical significance. These data  
402 might indicate that degradation of connexin43 is increased in BT-IgSF knockout cultures and  
403 suggest that BT-IgSF contributes to the stabilization of connexin43. Furthermore, a change in  
404 the migration pattern of connexin43 in SDS-PAGE under chloroquine conditions was detected  
405 in astrocytes of both genotypes (Figure 3I). The connexin bands pattern became more diffuse,  
406 band P1 appeared weaker and all bands migrated at a slightly higher position - perhaps  
407 indicating increased phosphorylation. The latter shift was stronger in the control. In summary,  
408 in the absence of BT-IgSF degradation of connexin43 via the lysosome pathway is increased  
409 which might explain the reduced expression of connexin43 in the hippocampus and cortex of  
410 BT-IgSF<sup>-/-</sup>.

411 To test for subcellular localization defects of connexin43 in the absence of BT-IgSF we  
412 compared wildtype and BT-IgSF-deficient astrocytes by staining them with antibodies specific  
413 for different compartments including LAMP-1 (lysosomal-associated membrane protein 1),  
414 phalloidin (actin cytoskeleton), GM130 (cis-Golgi marker),  $\gamma$ -adaptin (secretory vesicles), and  
415 ZO-1 (sub compartments such as tight junctions at the cell surface). No increased co-  
416 localization between connexin43 and any of these subcellular markers was detected in mutants

417 indicated by a comparison of the Pearson correlation coefficients (Figure 4A to D). This might  
418 exclude that connexin43 gets retained in an intracellular compartment in BT-IgSF<sup>-/-</sup> astrocytes.  
419 Consequently, connexin43 clusters were found at the cell surface in close association with  
420 wheat germ agglutinin that was applied to living astrocyte cultures on ice (Figure 4E). Taken  
421 together these data do not support the notion that the absence of BT-IgSF reduces the expression  
422 of connexin43 in astrocytes via impaired intracellular trafficking.

423 We detected minimal co-localization between connexin43 and the tight junction protein  
424 ZO-1 (mean value of Pearson's R-value: 0.1631 for wildtype and 0.002 for knockout) that was  
425 further slightly decreased in the BT-IgSF knockout, possibly due to the fact that connexin43  
426 was present at reduced levels (Figure 4F). In addition, BT-IgSF itself showed very little co-  
427 localization with connexin43 (Figure 4G). The occasional co-localization observed could be  
428 due to the fact that all of these proteins are present at the plasma membrane, or might indicate  
429 weak and/or transient associations (mean value of Pearson's R-value: -0.004568). A direct  
430 association between BT-IgSF and connexin43 could not be demonstrated since the available  
431 antibodies failed to co-precipitate BT-IgSF and connexin43.

432 Previously published studies reported that both the tumor necrosis factor- $\alpha$  and  
433 interferon- $\gamma$  reduce the expression of connexin43 on astrocytes and enterocytes, which in turn  
434 impairs cell-cell communication (Hinkerohe et al., 2005; Leaphart et al., 2007; Meme et al.,  
435 2006; Zhang et al., 2015, 2013). Conversely, BT-IgSF (VSIG3) was found to inhibit the  
436 secretion of interferon- $\gamma$  and tumor necrosis factor- $\alpha$  of activated PBMCs and CD4-positive T-  
437 cells in cell culture assays (Xie et al., 2021). Therefore, we applied interferon- $\gamma$  and tumor  
438 necrosis factor- $\alpha$  to wildtype astrocyte cultures. Interestingly, BT-IgSF protein level was  
439 diminished in both treatments which might further strengthen our data on a functional link  
440 between BT-IgSF and connexin43 on astrocytes (Figure 4H and I). As expected connexin43  
441 was also found to be reduced (Figure 4J).

442

443 **Reduced astrocyte-astrocyte coupling in the hippocampus and cortex in the absence of**  
444 **BT-IgSF**

445

446 A typical feature of astrocytes in the brain is their organization in vast networks that  
447 communicate with one another via gap-junction channels formed by connexins (Giaume et al.,  
448 2010). In order to investigate the effect of BT-IgSF ablation on astrocytic network size in the  
449 hippocampus and cortex we performed dye-coupling experiments (see schemes shown in  
450 Figure 5A to C). Astrocytes were identified in acutely isolated mouse brain slices by  
451 sulforhodamine 101 that specifically labels astroglia (Nimmerjahn et al., 2004). Individual  
452 astrocytes in the hippocampus molecular layer or cortical layers II – IV from horizontal slices  
453 were dye-loaded with biocytin via patch pipette. Diffusion of the dye throughout the astrocytic  
454 network allows for the visualization and quantification of the extent of gap-junction mediated  
455 cell-cell coupling (Figure 5D).

456 In the hippocampus as well as in the cortex, the number of coupled astrocytes per  
457 injected cell was significantly decreased in mutant animals. 15 dye-filled slices from 3 control  
458 mice and 11 slices from 4 BT-IgSF knockout mice were used for immunohistochemical analysis  
459 of hippocampal coupled astrocytic networks. On average  $101 \pm 8.851$  (mean  $\pm$  SD) biocytin-  
460 positive hippocampal astrocytes were coupled in the wildtype, whereas in the knockout only  
461  $78 \pm 7.837$  (mean  $\pm$  SD) biocytin-positive astrocytes were found to form a network (Figure 4E  
462 to G). In the cortex the differences between wildtype and knockout were even more  
463 pronounced: on average  $118 \pm 20.95$  (mean  $\pm$  SD) astrocytes in control and only  $48 \pm 7.86$  (mean  
464  $\pm$  SD) in the BT-IgSF knockout form a network (11 dye-filled slices from 4 controls and 10  
465 slices from 4 knockouts) (Figure 5H to J). Extended Figure 5-1 illustrates the passive membrane  
466 properties of hippocampal astrocytes in both groups over the course of the dialysis period. We  
467 observed no significant differences in the current to voltage relationship, membrane resistance  
468 or membrane capacitance ( $p > 0.05$ ) between genotypes or between the start and the end of the

469 dialysis period, indicating that these factors were not responsible for the change in the extent of  
470 the astrocytic network. Similar results were obtained for passive membrane properties in  
471 cortical astrocytes. Further, neither the density of GFAP-positive astrocytes nor their  
472 complexity (arborization) was reduced in the absence of BT-IgSF, suggesting that altered  
473 morphological parameters of astrocytes are unlikely to cause reduced cell-cell coupling in the  
474 absence of BT-IgSF (Figure 5K to N).

475 In summary, we detected reduced astrocyte-astrocyte coupling in the hippocampus and  
476 the cortex in the absence of BT-IgSF. We assign this to the observed changes in connexin43  
477 expression, i.e., the reduction of the connexin43 protein levels and/or its altered clustered  
478 localization.

479

#### 480 **Absence of BT-IgSF disrupts the localization of connexin43 on ependymal cells**

481

482 Ependymal cells are specialized multi-ciliated glial cells that line the ventricles and form  
483 an interface between the cerebrospinal fluid (CSF) and brain parenchyma (Deng et al., 2023).  
484 These cells also express GFAP (Roessmann et al., 1980). Ependymal cells contact each other  
485 via connexin43 containing gap junctions and are implicated in barrier formation as well as the  
486 production and circulation of cerebrospinal fluid (Saunders et al., 2018). To ask whether the  
487 absence of BT-IgSF also affects the localization of connexin43 on ependymal cells, we  
488 characterized the expression of BT-IgSF in the brain by immunohistochemistry. We detected a  
489 strong localization of BT-IgSF on cells lining all brain ventricles at embryonic as well as  
490 postnatal stages, but only very weak staining in the neural tissue directly adjacent to the  
491 ependymal cell layer (Figure 6A, see also Extended Figure 6-1 for antibody specificity). Higher  
492 magnifications showed that BT-IgSF was found at the lateral and basal surfaces of ependymal  
493 cells, but not at the apical side that faces the ventricle (Figure 6B). The choroid plexus that  
494 expresses the related IgCAM CAR stained weakly for BT-IgSF (Figure 6C). Matching the

495 deficits that we found in astrocytes, we also found a decreased number of spots and an increased  
496 clustering of connexin43 in BT-IgSF mutant ependymal cells compared to wildtypes (Figure  
497 6D to G).

498

#### 499 **The localization of connexin36 in neurons is not affected by the absence of BT-IgSF**

500

501 In the brain, connexin43 is restricted to astrocytes, whereas connexin36 is the main  
502 connexin in neurons and is primarily expressed during embryonic and early postnatal  
503 developmental stages (Condorelli et al., 1998; Degen et al., 2004; Gulisano et al., 2000; Rubio  
504 and Nagy, 2015; Söhl et al., 1998). We therefore asked whether the absence of BT-IgSF also  
505 affects the localization of the gap junction protein connexin36 in neurons. Commercially  
506 available antibodies to connexin36 were of limited use in our hands, and we therefore generated  
507 a polyclonal antibody to the cytoplasmic stretch (residues 99 to 197) of mouse connexin36  
508 (Figure 7A - D). Although this antibody also showed some unspecific binding in Western blots,  
509 it clearly labeled connexin36 at a molecular mass of 34 kDa in wildtype but not in connexin36-  
510 deficient neural tissues (Figure 7D). The specificity of this antibody to connexin36 could also  
511 be demonstrated in sections of wildtype or connexin36-deficient brain tissue (Figure 7E). The  
512 strongest expression of connexin36 was detected in the midbrain and hindbrain at postnatal day  
513 10, while much weaker expression levels were found in the cerebellum, basal ganglia,  
514 hippocampus and cortex (Figure 7D). We used single molecule fluorescent in situ hybridization  
515 (using RNAscope) to define the neuronal cell types expressing *Bt-igsf* mRNAs, and in the  
516 midbrain observed co-expression with *vGlut1* and *GAD65*, indicating that *Bt-igsf* is expressed  
517 in both excitatory and inhibitory neurons (Figure 7F). Similar expression patterns were seen in  
518 the hippocampus (Extended Figure 2-2). Since the strongest expression of connexin36 was  
519 detected in the midbrain, we analyzed this region in more depth. No differences in the  
520 localization or expression of connexin36 protein were detected in the absence of BT-IgSF in

521 the midbrain and hindbrain (Figure 7G to K). We conclude that BT-IgSF modulates the  
522 expression of connexin43 specifically in astrocytes and ependymal cells, but does not affect  
523 localization or clustering of connexin36 in neurons.

524

## 525 **Discussion**

526 Here we show that the Ig cell adhesion molecule BT-IgSF (IgSF11/VSIG-3)) is highly  
527 expressed on astrocytes and ependymal cells of the mouse brain. Our functional analysis  
528 demonstrates that BT-IgSF is essential for the correct expression and subcellular localization  
529 of connexin43 in astrocytes and ependymal cells. In the absence of BT-IgSF, the level of  
530 connexin43 protein is severely reduced and fewer but larger clusters of connexin43 are formed  
531 on the surface of astrocytes and ependymal cells in the brain. Importantly, our analysis of gap  
532 junction coupling in BT-IgSF knockouts revealed a reduced astrocytic network in the cortex  
533 and hippocampus. However, this impaired coupling was not due to morphological changes of  
534 astrocytes in the absence of BT-IgSF. Astrocytes generate a complex syncytial network  
535 allowing them to interact with many neighboring cells to control a number of physiological  
536 processes like neurotransmission and disruptions of gap junction coupling are found in a broad  
537 spectrum of diseases such as neurodegeneration or epilepsy (Bedner and Steinhäuser, 2023;  
538 Huang et al., 2021; Mayorquin et al., 2018; Mazaud et al., 2021). A change in the localization  
539 pattern or expression level of connexin36 in neurons was not detected in the absence of BT-  
540 IgSF.

541 BT-IgSF is a member of a small and evolutionarily conserved subfamily of IgCAMs of  
542 which CAR was the founding member. This set of proteins mediates homotypic cell adhesion,  
543 share a common overall extracellular domain structure and a highly related amino acid  
544 sequence. A number of studies that relied on mouse mutants suggested that these proteins might  
545 undertake similar functions as they help to organize or regulate gap junctions in a variety of cell



546 types (Falk, 2020; Rathjen, 2020). For example, in the absence of CAR, connexin43 and 45 are  
547 reduced in the heart, resulting in impaired electrical conduction at the atrioventricular node  
548 (Lim et al., 2008; Lisewski et al., 2008; Pazirandeh et al., 2011). In addition, cultured embryonic  
549 CAR-deficient cardiomyocytes showed increased calcium cycling, increased beating  
550 frequency, altered connexin43 clustering and impaired dye coupling (Matthaeus et al., 2023).  
551 Another example is CLMP as the absence of this adhesion protein impaired the function in  
552 smooth muscle cells of the intestine and ureter. Accordingly, uncoordinated calcium signaling  
553 provoked a disturbed contraction of the intestine and ureter. Notably, the level of connexin43  
554 and 45 proteins, but not their mRNAs, was severely reduced in the smooth muscle layers  
555 (Langhorst et al., 2018; Rathjen and Jüttner, 2023). Our studies on BT-IgSF described here  
556 provide an additional example of the way this subgroup of proteins plays a part in gap junction  
557 mediated cell-cell communication. The absence of BT-IgSF also affects the expression and  
558 localization pattern of connexin43 in astrocytes and ependymal cells. This is consistent with  
559 previously published data on the mis-localization of connexin43 in Sertoli cells of the testes,  
560 which leads to infertility and the functional impairment of the blood-testes-barrier (Pelz et al.,  
561 2017). Thus, all three members of the family, BT-IgSF, CLMP and CAR, are required for  
562 appropriate gap junction mediated cell-cell communication.

563

#### 564 **How might BT-IgSF exert its function on connexin43 in astrocytes?**

565

566 Connexin43, much like other connexins, has a dynamic “life cycle” and possesses a  
567 half-life time of about 1-5 hours. Furthermore, connexins have a complex biosynthesis and can  
568 be degraded by multiple pathways. Many proteins are known to interact with connexins during  
569 all stages of the life cycle of a gap junction (Falk et al., 2016; Solan and Lampe, 2016). The  
570 reduced expression of connexin43 in BT-IgSF knockout astrocytes appears to be caused by  
571 increased degradation as revealed by our lysosomal pathway inhibition experiments and might

572 indicate a stabilization function of BT-IgSF on connexin43 at gap junctions. However, the  
573 intracellular localization of connexin43 to specific compartments was not altered, suggesting  
574 that intracellular trafficking of connexin43 might not be disturbed in the absence of BT-IgSF.  
575 The decreased amount of connexin43 might result in increased clustering at the cell surface and  
576 might therefore be a secondary effect. Interestingly, treatment of astrocyte cultures with tumor  
577 necrosis factor- $\alpha$  or interferon- $\gamma$  caused a reduction of BT-IgSF that parallels the decrease of  
578 connexin43 by these factors. The latter finding was previously described on enterocytes of the  
579 intestine and on astrocytes (Hinkerohe et al., 2005; Leaphart et al., 2007; Meme et al., 2006;  
580 Zhang et al., 2015, 2013). Therefore, cytokines might be players that regulate the expression of  
581 BT-IgSF protein that in turn regulates connexin43 expression or localization. Reduced  
582 astrocyte-astrocyte coupling was also recently described in knockdown experiments of the Ig  
583 cell adhesion molecule HepaCAM (also termed GlialCAM) that, at the structural level is only  
584 distantly related to CAR subgroup members (Favre-Kontula et al., 2008; Moh et al., 2005). The  
585 authors found a reduced morphological complexity, including arborization of astrocytic  
586 protrusions, and a reduction in the territory covered by astrocytes. In addition, increased  
587 clustering of connexin43 was found in HepaCAM mutants and was accompanied by decreased  
588 dye coupling (Baldwin et al., 2021). Except for the increased clustering of connexin43 we did  
589 not detect similar morphological changes in astrocytes of BT-IgSF knockouts, nor did we find  
590 a reduction in astrocyte cell density in the molecular layer of the hippocampus. Moreover,  
591 HepaCAM is strongly expressed in the white matter, implicated in leukodystrophy and  
592 regulates the activity of glioblastoma cells (De et al., 2023; Favre-Kontula et al., 2008;  
593 Jeworutzki et al., 2012; López-Hernández et al., 2011) whereas the overall structure of the brain  
594 appears not to be affected by the absence of BT-IgSF (see Figures 1B, 1D, 6A, 2-1, 6-1).  
595 Therefore, HepaCAM and BT-IgSF seemingly play different roles, although in both cases their  
596 mutation resulted in impaired coupling. Furthermore, biochemical experiments established the  
597 direct association of HepaCAM with connexin43 at the cell surface (Baldwin et al., 2021; Wu

598 et al., 2016). By contrast, based on our co-localization studies in cultured astrocytes, we only  
599 occasionally detected BT-IgSF in close proximity with connexin43 at the cell surface of  
600 astrocytes, and we could not detect a direct interaction between the two proteins in co-  
601 precipitation experiments.

602 Co-localization of BT-IgSF with the scaffolding protein ZO-1 (Zona Occludens-1) at  
603 the cell surface was detected in Sertoli cells in confocal images (Pelz et al., 2017). BT-IgSF  
604 harbors a PDZ binding motif at its C-terminal domain and scaffolding proteins such as ZO-1  
605 bind via a PDZ domain to most connexins (Hervé et al., 2014). Therefore, one might speculate  
606 that ZO-1 binds to BT-IgSF via its PDZ domain1, and to connexin43 via its PDZ domain 2 thus  
607 regulating connexin43 localization (Duffy et al., 2002). Furthermore, ZO-1 has been shown to  
608 control gap junction assembly as well as localization and influences plaque size in cell cultures  
609 (Hunter et al., 2005; Laing et al., 2005; Rhett et al., 2011). A frameshift mutation in the  
610 connexin43 gene in human patients suffering from oculo-dento digital dysplasia disrupts the  
611 connexin43-ZO-1 interaction (Bock et al., 2013; van Steensel et al., 2005). Despite these  
612 findings in other cell types, co-localization of ZO-1 with connexin43 or co-localization of BT-  
613 IgSF with connexin43 was only rarely detected at the plasma membrane of astrocytes.  
614 Nevertheless, a transient association of these components cannot be excluded. Additional  
615 studies with mice expressing mutant versions of BT-IgSF and ZO-1 to investigate possible  
616 interactions between BT-IgSF, ZO-1 and connexin43 might clarify whether these complexes  
617 play a role for connexin43 assembly or in stabilizing connexin43 at the plasma membrane of  
618 astrocytes. Currently the question of precisely how BT-IgSF controls connexin43 localization  
619 and expression needs to be investigated further. Additional studies are needed to thoroughly  
620 understand a possible signal transduction pathway downstream of BT-IgSF that modulates the  
621 de novo incorporation or removal of connexin43 to or from the plasma membrane.

622

623 **BT-IgSF might have different functions in neurons and glial cells**

624

625           Previously published knockdown studies using cultured hippocampal neurons from the  
626 CA1 region implicated BT-IgSF (IgSF11) in synaptic transmission through interactions with  
627 PSD95 and AMPA receptors (Jang et al., 2015). In these *in vitro* experiments, the BT-IgSF  
628 (IgSF11) knockdown caused increased mobility and endocytosis of AMPA receptors,  
629 suggesting that BT-IgSF is important for the stabilization of AMPA receptors in the neuronal  
630 plasma membrane. In accordance, BT-IgSF-deficient mice revealed a moderately decreased  
631 excitatory synaptic strength in the dentate gyrus and enhanced long-term potentiation in CA1  
632 (Jang et al., 2015). Furthermore, BT-IgSF (IgSF11) was found to regulate the innervation of  
633 axons of chandelier cells on initial axon segments of pyramidal neurons (Hayano et al., 2021).  
634 To verify if our findings also apply to connexin localization in neurons, we extended our study  
635 and analyzed localization and expression of connexin36, the main neuronal connexin  
636 (Condorelli et al., 1998; Degen et al., 2004; Gulisano et al., 2000; Rubio and Nagy, 2015; Söhl  
637 et al., 1998). No differences in the localization or expression of connexin36 protein were  
638 detected in the absence of BT-IgSF in the midbrain. We conclude that BT-IgSF might have a  
639 different function in astrocytes and neurons, specifically modulating the expression of  
640 connexin43 in astrocytes and ependymal cells, but not affecting the distribution of connexin36  
641 in neurons.

642

#### 643 **What might be the consequences of astrocyte network disturbance for neuronal function?**

644

645           Astrocytes form an elaborate network to control a number of physiological processes in  
646 the brain. Disrupted communication of astrocytes in the absence of BT-IgSF could interfere  
647 with the coordination of astrocytic calcium waves or might affect synaptic activity. The close  
648 contact of astrocytic branches with synapses allows astrocytes to sense neuronal activity via  
649 their ion channels and neurotransmitter receptors (Ventura and Harris, 1999). Disruption of

650 astrocytic networks for example by inactivation of connexin43 and 30 reduced synaptic  
651 transmission (Charvériat et al., 2017; Giaume et al., 2010; Hardy et al., 2021; Pannasch et al.,  
652 2011; Perea et al., 2009; Pereda, 2014). Accordingly, connexin30 and astrocyte-targeted  
653 connexin43 knockout mice as well as connexin43 and 30 double knockout mice display  
654 impaired performance in sensorimotor and spatial memory tasks (Lutz et al., 2009; Theis et al.,  
655 2003). Astrocyte coupling is also altered in epilepsy (Bedner and Steinhäuser, 2023;  
656 Steinhäuser and Boison, 2012). Decreased coupling among astrocytes promotes neuronal  
657 hyperexcitability and attenuates seizure-induced histopathological outcomes (Deshpande et al.,  
658 2020). Astrocytic dysfunction is implicated in a number of neurodevelopmental disorders  
659 (Molofsk et al., 2012; Tan et al., 2021). Whether the behavioral deficits observed in BT-IgSF  
660 knockouts are caused by reduced astrocyte-astrocyte coupling or by deficits in the AMPA  
661 receptor trafficking needs further investigation using astrocyte- or neuron-specific ablation of  
662 BT-IgSF (Montag et al., 2023).

663 In the brain and spinal cord, ependymal cells line the ventricles and bear multiple cilia  
664 that beat in a concerted manner at their apical surface to drive cerebrospinal fluid circulation  
665 (Spassky and Meunier, 2017). This unidirectional movement might be coordinated by gap  
666 junction mediated cell-cell communication. Consistent with this hypothesis, *zebrafish* embryos  
667 injected with connexin43 morpholinos and connexin43-deficient mouse embryos exhibit a  
668 decreased number of cilia as well as diminished beating (Zhang et al., 2020).

669 In conclusion, in the present study we identified BT-IgSF as a crucial molecular helper  
670 to establish correct localization of connexin43 on astrocytes and ependymal cells. In astrocytes,  
671 this is essential for effective cell-cell coupling. Whether BT-IgSF's selective absence in  
672 astrocytes or ependymal cells is also important for neurotransmission or the coordinated  
673 movement of cilia, respectively, should be investigated in future work.

674

675

676 **References**

677

678 Ahi EP, Sefc KM (2017) A gene expression study of dorso-ventrally restricted pigment pattern in adult  
679 fins of *Neolamprologus meeli*, an African cichlid species. *PeerJ* 5:e2843.

680 Baldwin KT, Tan CX, Strader ST, Jiang C, Savage JT, Elorza-Vidal X, Contreras X, Rülcke T,  
681 Hippenmeyer S, Estévez R, Ji RR, Eroglu C (2021) HepaCAM controls astrocyte self-organization  
682 and coupling. *Neuron* 109:2427–2442.e10.

683 Bedner P, Steinhäuser C (2023) Role of Impaired Astrocyte Gap Junction Coupling in Epileptogenesis.  
684 *Cells* 12:1669.

685 Bock M de, Kerrebrouck M, Wang N, Leybaert L (2013) Neurological manifestations of  
686 oculodentodigital dysplasia: A Cx43 channelopathy of the central nervous system? *Front*  
687 *Pharmacol* 4 SEP:1–21.

688 Charvériat M, Naus CC, Leybaert L, Sáez JC (2017) Connexin-Dependent Neuroglial Networking as a  
689 New Therapeutic Target. *Front Cell Neurosci* 11:1–14.

690 Chen B, Zhu G, Yan A, He J, Liu Y, Li L, Yang X, Dong C, Kee K (2021) IGSF11 is required for pericentric  
691 heterochromatin dissociation during meiotic diplotene. *PLoS Genet* 17.

692 Condorelli DF, Parenti R, Spinella F, Salinaro AT, Belluardo N, Cardile V, Cicirata F (1998) Cloning of a  
693 new gap junction gene (Cx36) highly expressed in mammalian brain neurons. *European Journal*  
694 *of Neuroscience* 10:1202–1208.

695 De A, Lattier JM, Morales JE, Kelly JR, Zheng X, Chen Z, Sebastian S, Nassiri Toosi Z, Huse JT, Lang FF,  
696 McCarty JH (2023) Glial Cell Adhesion Molecule (GlialCAM) Determines Proliferative Versus  
697 Invasive Cell States in Glioblastoma. *The Journal of Neuroscience* JN-RM-1401-23.

698 Degen J, Meier C, van der Giessen RS, Söhl G, Petrasch-Parwez E, Urschel S, Dermietzel R, Schilling K,  
699 de Zeeuw CI, Willecke K (2004) Expression Pattern of lacZ Reporter Gene Representing  
700 Connexin36 in Transgenic Mice. *Journal of Comparative Neurology* 473:511–525.

701 Deng S, Gan L, Liu C, Xu T, Zhou S, Guo Y, Zhang Z, Yang GY, Tian H, Tang Y (2023) Roles of Ependymal  
702 Cells in the Physiology and Pathology of the Central Nervous System. *Aging Dis*.

703 Dermietzel R, Traub O, Hwang TK, Beyer E, Bennett M v, Spray DC, Willecke K (1989) Differential  
704 expression of three gap junction proteins in developing and mature brain tissues. *Proc Natl*  
705 *Acad Sci U S A* 86:10148–10152.

706 Deshpande T, Li T, Henning L, Wu Z, Müller J, Seifert G, Steinhäuser C, Bedner P (2020) Constitutive  
707 deletion of astrocytic connexins aggravates kainate-induced epilepsy. *Glia* 68:2136–2147.

708 Duffy HS, Delmar M, Spray DC (2002) Formation of the gap junction nexus: binding partners for  
709 connexins. *Journal of Physiology-Paris* 96:243–249.

710 Eom DS, Inoue S, Patterson LB, Gordon TN, Slingwine R, Kondo S, Watanabe M, Parichy DM (2012)  
711 Melanophore Migration and Survival during Zebrafish Adult Pigment Stripe Development  
712 Require the Immunoglobulin Superfamily Adhesion Molecule Igsf11. *PLoS Genet* 8:e1002899.

713 Falk MM (2020) Do CAR and CAR family members aid in gap junction formation? *BioEssays*  
714 42:e2000276.

715 Falk MM, Bell CL, Kells Andrews RM, Murray SA (2016) Molecular mechanisms regulating formation,  
716 trafficking and processing of annular gap junctions. *BMCCell Biol* 17 Suppl 1:22–27.

717 Favre-Kontula L, Rolland A, Bernasconi L, Karmirantzou M, Power C, Antonsson B, Boschert U (2008)  
718 GlialCAM, an immunoglobulin-like cell adhesion molecule is expressed in glial cells of the  
719 central nervous system. *Glia* 56:633–645.

720 Giaume C, Koulakoff A, Roux L, Holcman D, Rouach N (2010) Astroglial networks: A step further in  
721 neuroglial and gliovascular interactions. *Nat Rev Neurosci* 11:87–99.

722 Güldenagel M, Ammermüller J, Feigenspan A, Teubner B, Degen J, Söhl G, Willecke K, Weiler R (2001)  
723 Visual transmission deficits in mice with targeted disruption of the gap junction gene  
724 connexin36. *Journal of Neuroscience* 21:6036–6044.

725 Gulisano M, Parenti R, Spinella F, Cicirata F (2000) Cx36 is dynamically expressed during early  
726 development of mouse brain and nervous system. *Neuroreport* 11:3823–3828.

727 Haffter P, Odenthal J, Mullins MC, Lin S, Farrell MJ, Vogelsang E, Haas F, Brand M, van Eeden FJ,  
728 Furutani-Seiki M, Granato M, Hammerschmidt M, Heisenberg CP, Jiang YJ, Kane DA, Kelsh RN,  
729 Hopkins N, Nusslein-Volhard C (1996) Mutations affecting pigmentation and shape of the adult  
730 zebrafish. *Dev Genes Evol* 206:260–276.

731 Harada H, Suzu S, Hayashi Y, Okada S (2005) BT-IgSF, a novel immunoglobulin superfamily protein,  
732 functions as a cell adhesion molecule. *JCell Physiol* 204:919–926.

733 Hardy E, Rancillac A, Cohen-salmon M, Rouach N (2021) Astroglial Cx30 differentially impacts  
734 synaptic activity from hippocampal principal cells and interneurons. *Glia* 69:2178–2198.

735 Hayano Y, Ishino Y, Hyun JH, Orozco CG, Steinecke A, Potts E, Oishi Y, Thomas CI, Guerrero-Given D,  
736 Kim E, Kwon H-B, Kamasawa N, Taniguchi H (2021) IgSF11 homophilic adhesion proteins  
737 promote layer-specific synaptic assembly of the cortical interneuron subtype. *Sci Adv* 7:1–14.

738 Hervé JC, Derangeon M, Sarrouilhe D, Bourmeyster N (2014) Influence of the scaffolding protein  
739 Zonula Occludens (ZO) on membrane channels. *Biochim Biophys Acta Biomembr* 1838:595–  
740 604.

741 Higashine K, Hashimoto K, Tsujimoto E, Oishi Y, Hayashi Y, Miyamoto Y (2018) Promotion of  
742 differentiation in developing mouse cerebellar granule cells by a cell adhesion molecule BT-IgSF.  
743 *Neurosci Lett* 686:87–93.

744 Hinkerohe D, Smikalla D, Haghikia A, Heupel K, Haase CG, Dermietzel R, Faustmann PM (2005) Effects  
745 of cytokines on microglial phenotypes and astroglial coupling in an inflammatory coculture  
746 model. *Glia* 52:85–97.

747 Huang X, Su Y, Wang N, Li H, Li Z, Yin G, Chen H, Niu J, Yi C (2021) Astroglial Connexins in  
748 Neurodegenerative Diseases. *Front Mol Neurosci* 14:1–9.

749 Hunter AW, Barker RJ, Zhu C, Gourdie RG (2005) Zonula occludens-1 alters connexin43 gap junction  
750 size and organization by influencing channel accretion. *Mol Biol Cell* 16:5686–5698.

751 Irion U, Frohnhof HG, Krauss J, Colak Champollion T, Maischein H-M, Geiger-Rudolph S, Weiler C,  
752 Nusslein-Volhard C (2014) Gap junctions composed of connexins 41.8 and 39.4 are essential for  
753 colour pattern formation in zebrafish. *Elife* 3:e05125.

754 Jang S et al. (2015) Synaptic adhesion molecule IgSF11 regulates synaptic transmission and plasticity.  
755 *Nat Neurosci* 19:84–93.

756 Jeworutzki E, López-Hernández T, Capdevila-Nortes X, Sirisi S, Bengtsson L, Montolio M, Zifarelli G,  
757 Arnedo T, Müller CS, Schulte U, Nunes V, Martínez A, Jentsch TJ, Gasull X, Pusch M, Estévez R  
758 (2012) GlialCAM, a Protein Defective in a Leukodystrophy, Serves as a ClC-2 Cl<sup>-</sup> Channel  
759 Auxiliary Subunit. *Neuron* 73:951–961.

760 Katoh MM, Katoh MM (2003) IGSF11 gene, frequently up-regulated in intestinal-type gastric cancer,  
761 encodes adhesion molecule homologous to CXADR, FLJ22415 and ESAM. *Int J Oncol* 23:525–  
762 531.

763 Kim GM, Kim J, Lee J-Y, Park M-C, Lee SY (2023) IgSF11 deficiency alleviates osteoarthritis in mice by  
764 suppressing early subchondral bone changes. *Exp Mol Med*.

765 Kim H, Takegahara N, Choi Y (2023) IgSF11-mediated phosphorylation of pyruvate kinase M2  
766 regulates osteoclast differentiation and prevents pathological bone loss. *Bone Res* 11:17.

767 Kim H, Takegahara N, Walsh MC, Middleton SA, Yu J, Shirakawa J, Ueda J, Fujihara Y, Ikawa M, Ishii  
768 M, Kim J, Choi Y (2020) IgSF11 regulates osteoclast differentiation through association with the  
769 scaffold protein PSD-95. *Bone Res* 8:5.

770 Laing JG, Chou BC, Steinberg TH (2005) ZO-1 alters the plasma membrane localization and function of  
771 Cx43 in osteoblastic cells. *J Cell Sci* 118:2167–2176.

772 Laird DW, Lampe PD (2018) Therapeutic strategies targeting connexins. *Nat Rev Drug Discov* 17:905–  
773 921.

774 Langhorst H, Jüttner R, Groneberg D, Mohtashamdolatsahi A, Pelz L, Purfürst B, Schmidt-Ott KM,  
775 Friebe A, Rathjen FG (2018) The IgCAM CLMP regulates expression of Connexin43 and  
776 Connexin45 in intestinal and ureteral smooth muscle contraction in mice. *Dis Model Mech*  
777 11:dmm032128.

778 Leaphart CL, Qureshi F, Cetin S, Li J, Dubowski T, Batey C, Beer-Stolz D, Guo F, Murray SA, Hackam DJ  
779 (2007) Interferon- $\gamma$  Inhibits Intestinal Restitution by Preventing Gap Junction Communication  
780 Between Enterocytes. *Gastroenterology* 132:2395–2411.

781 Li MWM, Mruk DD, Lee WM, Cheng CY (2010) Connexin 43 is critical to maintain the homeostasis of  
782 the blood-testis barrier via its effects on tight junction reassembly. *Proc Natl Acad Sci U S A*  
783 107:17998–18003.

784 Lim BK, Xiong D, Dorner A, Youn TJ, Yung A, Liu TI, Gu Y, Dalton ND, Wright AT, Evans SM, Chen J,  
785 Peterson KL, McCulloch AD, Yajima T, Knowlton KU (2008) Coxsackievirus and adenovirus  
786 receptor (CAR) mediates atrioventricular-node function and connexin 45 localization in the  
787 murine heart. *J Clin Invest* 118:2758–2770.

788 Lisewski U, Shi Y, Wrackmeyer U, Fischer R, Chen C, Schirdewan A, Jüttner R, Rathjen F, Poller W,  
789 Radke MHM, Gotthardt M (2008) The tight junction protein CAR regulates cardiac conduction  
790 and cell-cell communication. *J Exp Med* 205:2369–2379.



791 López-Hernández T, Ridder MC, Montolio M, Capdevila-Nortes X, Polder E, Sirisi S, Duarri A, Schulte  
792 U, Fakler B, Nunes V, Scheper GC, Martínez A, Estévez R, Van Der Knaap MS (2011) Mutant  
793 GlialCAM causes megalencephalic leukoencephalopathy with subcortical cysts, benign familial  
794 macrocephaly, and macrocephaly with retardation and autism. *Am J Hum Genet* 88:422–432.

795 Lutz SE, Zhao Y, Gulinello M, Lee SC, Raine CS, Brosnan CF (2009) Deletion of astrocyte connexins 43  
796 and 30 leads to a dysmyelinating phenotype and hippocampal CA1 vacuolation. *Journal of*  
797 *Neuroscience* 29:7743–7752.

798 Maglione M, Tress O, Haas B, Karram K, Trotter J, Willecke K, Kettenmann H, Trotter J, Maglione M,  
799 Karram K, Tress O, Haas B, Kettenmann H (2010) Oligodendrocytes in mouse corpus callosum  
800 are coupled via gap junction channels formed by connexin47 and connexin32. *Glia* 58:1104–  
801 1117.

802 Matthaeus C, Jüttner R, Gotthardt M, Rathjen FG (2022) The IgCAM CAR Regulates Gap Junction-  
803 Mediated Coupling on Embryonic Cardiomyocytes and Affects Their Beating Frequency. *Life*  
804 13:14.

805 Mayorquin LC, Rodriguez A v., Sutachan JJ, Albarracín SL (2018) Connexin-mediated functional and  
806 metabolic coupling between astrocytes and neurons. *Front Mol Neurosci* 11:1–10.

807 Mazaud D, Capano A, Rouach N (2021) The many ways astroglial connexins regulate  
808 neurotransmission and behavior. *Glia* 69:2527–2545.

809 McCarthy K, de Vellis J (1980) Preparation of separate astroglial and oligodendroglial cell cultures  
810 from rat cerebral tissue. *JCell Biol* 85:890–902.

811 Meme W, Calvo C, Froger N, Ezan P, Amigou E, Koulakoff A, Giaume C (2006) Proinflammatory  
812 cytokines released from microglia inhibit gap junctions in astrocytes: potentiation by  $\beta$ -amyloid.  
813 *The FASEB Journal* 20:494–496.

814 Moh MC, Zhang C, Luo C, Lee LH, Shen S (2005) Structural and functional analyses of a novel Ig-like  
815 cell adhesion molecule, hepaCAM, in the human breast carcinoma MCF7 cells. *Journal of*  
816 *Biological Chemistry* 280:27366–27374.

817 Molofsk A v., Krenick R, Ullian E, Tsai HH, Deneen B, Richardson WD, Barres BA, Rowitch DH (2012)  
818 Astrocytes and disease: A neurodevelopmental perspective. *Genes Dev* 26:891–907.

819 Montag D, Pelz L, Rathjen FG (2023) Lack of the Ig cell adhesion molecule BT-IgSF (IgSF11) induced  
820 behavioral changes in the open maze, water maze and resident intruder test. *PLoS One* 18:4–  
821 15.

822 Musil LS, Goodenough DA (1991) Biochemical analysis of connexin43 intracellular transport,  
823 phosphorylation, and assembly into gap junctional plaques. *Journal of Cell Biology* 115:1357–  
824 1374.

825 Nagy JI, Dudek FE, Rash JE (2004) Update on connexins and gap junctions in neurons and glia in the  
826 mammalian nervous system. *Brain Res Rev* 47:191–215.

827 Owczarek C, Elmasry Y, Parsons M (2023) Contributions of coxsackievirus adenovirus receptor to  
828 tumorigenesis. *Biochem Soc Trans* 51:1143–1155.

829 Pannasch U, Vargova L, Reingruber J, Ezan P, Holcman D, Giaume C, Sykova E, Rouach N (2011)  
830 Astroglial networks scale synaptic activity and plasticity. *Proceedings of the National Academy*  
831 *of Sciences* 108:8467–8472.

832 Pazirandeh A et al. (2011) Multiple phenotypes in adult mice following inactivation of the  
833 Coxsackievirus and Adenovirus Receptor (Car) gene. *PLoS One* 6:e20203.

834 Pelz L, Purfürst B, Rathjen FG (2017) The cell adhesion molecule BT-IgSF is essential for a functional  
835 blood-testis barrier and male fertility in mice. *Journal of Biological Chemistry* 292:21490–21503.

836 Perea G, Navarrete M, Araque A (2009) Tripartite synapses: astrocytes process and control synaptic  
837 information. *Trends Neurosci* 32:421–431.

838 Pereda AE (2014) Electrical synapses and their functional interactions with chemical synapses. *Nat*  
839 *Rev Neurosci* 15:250–263.

840 Raschperger E, Engstrom U, Pettersson RF, Fuxe J (2004) CLMP, a novel member of the CTX family  
841 and a new component of epithelial tight junctions. *Journal of Biological Chemistry* 279:796–804.

842 Rathjen FG (2020) The CAR group of Ig cell adhesion proteins – Regulators of gap junctions ?  
843 *BioEssays* 42:1–11.

844 Rathjen FG, Jüttner R (2023) The IgSF Cell Adhesion Protein CLMP and Congenital Short Bowel  
845 Syndrome (CSBS). *Int J Mol Sci* 24:5719.

846 Rhett JM, Jourdan J, Gourdie RG (2011) Connexin 43 connexon to gap junction transition is regulated  
847 by zonula occludens-1. *Mol Biol Cell* 22:1516–1528.

848 Richter N, Wendt S, Georgieva PB, Hambardzumyan D, Nolte C, Kettenmann H (2014) Glioma-  
849 associated microglia and macrophages/monocytes display distinct electrophysiological  
850 properties and do not communicate via gap junctions. *Neurosci Lett* 583:130–135.

851 Roessmann U, Velasco ME, Sindely SD, Gambetti P (1980) GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP)  
852 IN EPENDYMAL CELLS DURING DEVELOPMENT. AN IMMUNOCYTOCHEMICAL STUDY, *Brain*  
853 *Research*.

854 Rubio ME, Nagy JI (2015) Connexin36 expression in major centers of the auditory system in the CNS  
855 of mouse and rat: Evidence for neurons forming purely electrical synapses and morphologically  
856 mixed synapses. *Neuroscience* 303:604–629.

857 Saunders NR, Dziegielewska KM, Møllgård K, Habgood MD (2018) Physiology and molecular biology  
858 of barrier mechanisms in the fetal and neonatal brain. *J Physiol* 596:5723–5756.

859 Schrezenmeier E, Dörner T (2020) Mechanisms of action of hydroxychloroquine and chloroquine:  
860 implications for rheumatology. *Nat Rev Rheumatol*.

861 Singh AP, Nusslein-Volhard C (2015) Zebrafish stripes as a model for vertebrate colour pattern  
862 formation. *Curr Biol* 25:R81–R92.

863 Söhl G, Degen J, Teubner B, Willecke K (1998) The murine gap junction gene connexin36 is highly  
864 expressed in mouse retina and regulated during brain development. *FEBS Lett* 428:27–31.

865 Solan JL, Lampe PD (2016) Kinase programs spatiotemporally regulate gap junction assembly and  
866 disassembly: Effects on wound repair. *SeminCell DevBiol* 50:40–48.

867 Spassky N, Meunier A (2017) The development and functions of multiciliated epithelia. *Nat Rev Mol*  
868 *Cell Biol* 18:423–436.

869 Steinhäuser C, Boison D (2012) Epilepsy: Crucial role for astrocytes. *Glia* 60:1191.

870 Suzu S, Hayashi Y, Harumi T, Nomaguchi K, Yamada M, Hayasawa H, Motoyoshi K (2002) Molecular  
871 cloning of a novel immunoglobulin superfamily gene preferentially expressed by brain and  
872 testis. *BiochemBiophysResCommun* 296:1215–1221.

873 Tan CX, Burrus Lane CJ, Eroglu C (2021) Role of astrocytes in synapse formation and maturation. *Curr*  
874 *Top Dev Biol* 142:371–407.

875 Theis M, Jauch R, Zhuo L, Speidel D, Wallraff A, Döring B, Frisch C, Söhl G, Teubner B, Euwens C,  
876 Huston J, Steinhäuser C, Messing A, Heinemann U, Willecke K (2003) Accelerated hippocampal  
877 spreading depression and enhanced locomotory activity in mice with astrocyte-directed  
878 inactivation of connexin43. *Journal of Neuroscience* 23:766–776.

879 van Steensel MAM, Spruijt L, van der Burgt I, Bladergroen RS, Vermeer M, Steijlen PM, van Geel M  
880 (2005) A 2-bp deletion in the GJA1 gene is associated with oculo-dento-digital dysplasia with  
881 palmoplantar keratoderma. *Am J Med Genet A* 132A:171–174.

882 Ventura R, Harris KM (1999) Three-dimensional relationships between hippocampal synapses and  
883 astrocytes. *Journal of Neuroscience* 19:6897–6906.

884 Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, Wu X, Vo HT, Ma XJ, Luo Y (2012) RNAscope: A  
885 novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. *Journal of*  
886 *Molecular Diagnostics* 14:22–29.

887 Wang J et al. (2019) VSIG-3 as a ligand of VISTA inhibits human T-cell function. *Immunology* 156:74–  
888 85.

889 Watanabe M, Iwashita M, Ishii M, Kurachi Y, Kawakami A, Kondo S, Okada N (2006) Spot pattern of  
890 leopard Danio is caused by mutation in the zebrafish connexin41.8 gene. *EMBO Rep* 7:893–897.

891 Watanabe M, Kondo S (2012) Changing clothes easily: connexin41.8 regulates skin pattern variation.  
892 *Pigment Cell Melanoma Res* 25:326–330.

893 Willecke K, Eiberger J, Degen J, Eckardt D, Romualdi A, Guldenagel M, Deutsch U, Sohl G (2002)  
894 Structural and functional diversity of connexin genes in the mouse and human genome.  
895 *BiolChem* 383:725–737.

896 Wu M, Moh MC, Schwarz H (2016) HepaCAM associates with connexin 43 and enhances its  
897 localization in cellular junctions. *Sci Rep* 6:36218.

898 Xie X, Chen C, Chen W, Jiang J, Wang L, Li T, Sun H, Liu J (2021) Structural Basis of VSIG3: The Ligand  
899 for VISTA. *Front Immunol* 12.

900 Zhang FF, Morioka N, Kitamura T, Hisaoka-Nakashima K, Nakata Y (2015) Proinflammatory cytokines  
901 downregulate connexin 43-gap junctions via the ubiquitin-proteasome system in rat spinal  
902 astrocytes. *Biochem Biophys Res Commun* 464:1202–1208.

903 Zhang FF, Morioka N, Nakashima-Hisaoka K, Nakata Y (2013) Spinal astrocytes stimulated by tumor  
904 necrosis factor- $\alpha$  and/or interferon- $\gamma$  attenuate connexin 43-gap junction via c-jun terminal  
905 kinase activity. *J Neurosci Res* 91:745–756.

906 Zhang J et al. (2020) Wnt-PLC-IP3-Connexin-Ca<sup>2+</sup> axis maintains ependymal motile cilia in zebrafish  
907 spinal cord. *Nat Commun* 11:1860.

908

909

## 910 **Figure Legends**

### 911 **Figure 1**

#### 912 **Impaired clustering of connexin43 in astrocytes in the absence of BT-IgSF.**

913 A and B) Overview of the location of connexin43 in coronal sections of the hippocampus from  
914 wildtype (A) and BT-IgSF-deficient (B) mice (10 weeks old). CA1, cornus ammonis 1; CA3,  
915 Cornus ammonis 3; DG, dentate gyrus; GCL, granule cell layer; ML, molecular layer. Scale  
916 bar, 100  $\mu$ m.

917 C) Higher magnification of the molecular layer of the dentate gyrus from adult wildtype and  
918 knockout mice stained by mAb anti-connexin43, rabbit anti-BT-IgSF and DAPI. Arrow heads  
919 indicate large connexin43 clusters.

920 D) Cortical astrocyte monolayer cultures from P3 wildtype or knockout mice at DIV14 stained  
921 by mAb anti-connexin43, rabbit anti-BT-IgSF and DAPI. Scale bar, 20 $\mu$ m.

922 E and F) Quantification of the connexin43 spots and cluster size on astrocytes in the  
923 hippocampus. In total 1652.5 $\pm$ 306.6 (mean  $\pm$  SD) and 505.4 $\pm$ 128.1 (mean  $\pm$  SD) connexin43  
924 spots from wildtype and BT-IgSF  $-/-$ , respectively, from 10 cryo-sections (63x objective) of  
925 three specimens of each genotype were counted. Nested t-test was applied.

926 H and I) Quantification of the connexin43 spots and cluster size of connexin43 on cultured  
927 cortical astrocytes. Control, 243 $\pm$ 65.1 (mean  $\pm$  SD); BT-IgSF $-/-$ , 132.9 $\pm$ 43.9 spots from 10 view  
928 fields (100x objective) from three independent cultures per genotype were counted. Nested t-  
929 test.

930 G and J) Cluster size distribution of connexin43 versus cluster number in the hippocampus or  
931 on astrocytes in culture (J).

932 Scale bar in B, 100  $\mu$ m; in C and D, 20 $\mu$ m.

933

934

935 **Figure 2**

936 **Expression of BT-IgSF on astrocytes (see Figure 2-1 for BT-IgSF antibody specificity and**  
937 **Figure 2-2 for BT-IgSF mRNA expression in neurons).**

938 A) Localization of BT-IgSF in hippocampus cells from P2-old mice cultured for 10 days *in*  
939 *vitro* and stained by guinea pig antibodies to GFAP and rabbit anti-BT-IgSF. Three independent  
940 cultures were analyzed. Scale bar, 20  $\mu$ m.

941 B) Western blot of extracts from an astrocyte culture using rabbit antibodies to BT-IgSF.  
942 Extracts from two cultures were mixed and three times analyzed by blots. Molecular mass  
943 markers are indicated at the left of the panel.

944 C) Cultured hippocampus cells were stained by antibodies to MAP2a/b and rabbit anti-BT-  
945 IgSF. Three cultures were analyzed. Scale bar, 30  $\mu$ m. BT-IgSF is found on GFAP astrocytes  
946 but rarely detectable on MAP2a/b-positive neurons by antibodies.

947 D) Localization of BT-IgSF in a coronal hippocampus section from an adult mouse. BT-IgSF  
948 is primarily found in the molecular layer and the subgranular zone. Higher magnification shows  
949 a widespread localization in the molecular layer probably not restricted to a specific cell type.  
950 Five independent experiments were done. CA1, cornus ammonis 1; CA3, Cornus ammonis 3;  
951 DG, dentate gyrus; GCL, granule cell layer; ML, molecular layer. Left and middle panel, scale  
952 bar 1 mm; right panel 20  $\mu$ m.

953 E) RNAscope of a coronal section of the hippocampus at P20 showing expression of *Bt-igsf*  
954 mRNA in GFAP-positive astrocytes in the molecular layer and hilus of the dentate gyrus. Three  
955 independent sections were analyzed. Scale bar, 50  $\mu$ m.

956 F) Higher magnifications of squares as indicated in E). Scale bar, 5  $\mu$ m.

957 G) Effective extraction of BT-IgSF from tissues requires SDS. Equal amounts of crude  
958 membrane fractions from brain (P56) were extracted with 1% TX100 or SDS. For specificity  
959 of the antibody knockout brain tissue is shown. Three independent extractions were done.

960 H and I) Different postnatal stages of brain extracts using SDS stained with anti-BT-IgSF are  
961 shown (n=3). BT-IgSF is primarily found at advanced postnatal stages. Anti-GAPDH indicates  
962 loading. J) For comparison GFAP expression is shown.

963

964

965 **Figure 3**

966 **Connexin43 but not connexin30 proteins are reduced in the hippocampus and cortex, and**  
967 **blockers of the protein biosynthesis and proteolysis show increased degradation of**  
968 **connexin43 in the absence of BT-IgSF.**

969 A, B and C) Western blots demonstrating reduction of connexin43 in crude membrane  
970 fractions from 8 weeks-old hippocampi or cortices of wildtype and BT-IgSF-deficient mice.  
971 The crude membrane fractions were first solubilized in 1% Triton-X100 and un-solubilized  
972 material was then solved in 1% SDS. 20 µg of protein was loaded per lane. Loading control is  
973 demonstrated by a monoclonal antibody to the heavy chain of clathrin. Quantification of band  
974 intensities are shown in B. For hippocampus 5 and 6 specimen for each genotype were  
975 analyzed for TX-100 and SDS, respectively; for cortex 7 and 7 for TX-100 and SDS,  
976 respectively. In Figure 3C for each condition 3 specimens were inspected.

977 Blot intensities of the BT-IgSF mutant were normalized to control (CON) values. p-values  
978 above the columns indicate significance to controls. Mann-Whitney-test.

979 For comparison quantification of Western blots of antibodies to connexin30 are shown in C.

980 D) The localization of connexin30 in the molecular layer of hippocampi is not affected by the  
981 absence of BT-IgSF. DG, dentate gyrus; ML, molecular layer. Scale bar, 20 µm.

982 E and F) The expression of GFAP is not reduced in the absence of BT-IgSF. Equal loading is  
983 indicated by an antibody to GAPDH. For each condition 4 specimens were analyzed.

984 G and H) Astrocytes treated with cycloheximide (100 µg/ml) for times indicated in the

985 Figures were lysed (1% SDS in TBS and 1 mM EDTA supplemented with protease blockers)

986 and boiled in SDS sample buffer. Equal amounts were loaded on 10 % SDS PAGE, blotted  
987 and analyzed with rabbit anti-connexin43. Equal loading was controlled by mAb to GAPDH.  
988 Quantification of all cycloheximide experiments was done using Image Lab software  
989 (BioRad). At each condition multiple cultures from 4 mice of each genotype were run on  
990 multiple Western blots (7 to 24). No significance was measured between genotypes; nested t-  
991 test and an outlier test were applied.

992 I and J) Blocking of lysosomal degradation by chloroquine (CQ) (100  $\mu$ M) for 4 hours in  
993 astrocyte cultures from control and BT-IgSF knockouts. At each condition multiple cultures  
994 from 3 mice of each genotype were run on multiple Western blots (16 to 20). Outlier-test and  
995 nested t-test were applied, in addition for 3J knockout data were analyzed by Mann-Whitney  
996 of the means of the blot replicates for each independent culture (p=0.0286).

997

#### 998 **Figure 4**

#### 999 **Subcellular localization of connexin43 is not impaired in the absence of BT-IgSF**

1000 A – D) The subcellular localization of connexin43 in the absence of BT-IgSF and wildtype  
1001 astrocytes was analyzed by using phalloidin or specific antibodies to intracellular subcellular  
1002 compartments. Cells from three independent cultures were fixed with 4%  
1003 paraformaldehyde/PBS (5 minutes on ice) before application of the antibodies and analyzed as  
1004 described in the Materials and Method section.

1005 A) mAb to  $\gamma$ -adaplin and rabbit anti-connexin43,

1006 B) mAb to GM130 and rabbit anti-connexin43,

1007 C) mAb to LAMP-1 and rabbit anti-connexin43,

1008 D) phalloidin-594 and rabbit anti-connexin43.

1009 E) Cell surface localization of connexin43 clusters on BT-IgSF-deficient astrocytes in culture.

1010 Living cells were incubated with WGA-488 for 45 minutes on ice, then fixed and

1011 permeabilized followed by staining with rabbit anti-connexin43. Connexin43 (Red) spots  
1012 were counted on BT-IgSF  $-/-$  astrocytes from three independent cultures (100x objective).  
1013 Strong co-localization was observed between WGA-488 (Green) and connexin43. Numbers  
1014 are as follows: Experiment 1: 470 connexin43-positive spots (95%) showed co-localization  
1015 with WGA, 29 not (10 cells analyzed). Experiment 2: 329 (98%) versus 3 (5 cells).  
1016 Experiment 3: 519 (98%) versus 14 (7 cells).  
1017 F) mAb to ZO-1 and rabbit anti-connexin43,  
1018 G) Rb96 to BT-IgSF and mAb to connexin43. Mean values and standard deviations of the  
1019 three independent cultures are:  $-0.02037$  (SD 0.2666),  $0.07$  (SD 0.2768) and  $-0.0063$  (SD  
1020 0.2334). The ONE-ANOVA value of 0.1632 indicates similarity between the three cultures.  
1021 In A to D and F)  $n=27-30$ , in G  $n=82$  images were analyzed for the calculation of the  
1022 Pearson's R value. The number of experimental replicates for 4A to G was 3. Nested t-test  
1023 was applied. Scale bar in A-D and F and G,  $10\ \mu\text{m}$ ; scale bar in E,  $5\ \mu\text{m}$ .  
1024 H – J) Expression of BT-IgSF protein is decreased in the presence of tumor necrosis factor- $\alpha$   
1025 (1 ng/ml) or interferon- $\gamma$  (10 ng/ml) on astrocytes in culture (H and I). Both reagents were  
1026 applied for 24 hr in DMEM without FCS. Four independent wildtype cultures were analyzed  
1027 in multiple Western blots (IFN- $\gamma$ : 14 and 15; TNF- $\alpha$ : 9 and 10). For comparison reduced  
1028 expression of connexin43 in the presence of tumor necrosis factor- $\alpha$  or interferon- $\gamma$  is shown  
1029 (J). Gels using antibodies to BT-IgSF were run under non-reducing conditions. Nested t-tests  
1030 were applied and additionally Mann-Whitney test for IFN- $\gamma$  or of TNF- $\alpha$  treatments of the  
1031 means of biological replicates were performed ( $p=0.0280$  and  $p=0.0286$ , respectively).

1032

### 1033 **Figure 5**

1034 **Impaired gap junction mediated coupling between astrocyte networks in the BT-IgSF**  
1035 **knockout mice (see Figure 5-1 for electrophysiological data).**



1036 A) Scheme of homophilic binding of BT-IgSF, B) connexin43 coupling and C) the dye filling  
1037 experiment to study gap junctional communication in astrocytes. PM – plasma membrane.  
1038 D) z-stack images of both genotypes of the immunohistochemical analysis for DAPI, biocytin,  
1039 BT-IgSF and GFAP staining in hippocampus. The right images show an overlay of all channels.  
1040 GCL, granular cell layer; ML, molecular layer. Scale bar, 100  $\mu$ m.  
1041 E - G) Scatter plots showing the network size (E, number of coupled cells), tracer spread  
1042 alongside (F, tracer-spread x) or perpendicular to the Schaffer collaterals (G, tracer-spread y).  
1043 15 dye-filled slices from 3 control mice and 11 slices from 4 BT-IgSF knockout mice were  
1044 analyzed. On average  $101 \pm 8.851$  (mean  $\pm$  SD) biocytin-positive hippocampal astrocytes were  
1045 coupled in the wildtype, whereas in the knockout only  $78 \pm 7.837$  (mean  $\pm$  SD) biocytin-positive  
1046 astrocytes were found to form a network. Nested t-test.  
1047 H - J) Scatter blots of dye-coupling of astrocytes in the cortex. On average  $118 \pm 20.95$  (mean  $\pm$   
1048 SD) astrocytes in control and  $48 \pm 7.86$  (mean  $\pm$  SD) in the BT-IgSF knockout form a network  
1049 (11 dye-filled slices from 4 controls and 10 slices from 4 knockouts). Nested t-test.  
1050 K) Area of individual cultured astrocytes is not affected by the absence of BT-IgSF (3  
1051 independent cultures of each genotype). Nested t-test.  
1052 L) Number of GFAP-positive astrocytes is not reduced in the absence of BT-IgSF. GFAP-  
1053 positive cells were counted in microscopic view fields ( $350 \mu\text{m} \times 350 \mu\text{m}$ ) in the molecular  
1054 layer of sections of hippocampi from wildtype and BT-IgSF knockout mice. 964 cells in 15  
1055 view fields and 616 cells in 9 view fields were counted for wildtype and knockout, respectively.  
1056 Numbers of replicates were 4 for the control and 3 for the BT-IgSF knockout. Nested t-test and  
1057 in addition Mann-Whitney of the means of the replicates ( $p=0.700$ ).  
1058 M) Images of GFAP-positive astrocytes in the molecular layer of the hippocampus from  
1059 wildtype and BT-IgSF-deficient mice indicating a similar morphology.  
1060 N) Branching of GFAP-positive cells remains unchanged in the absence of BT-IgSF. Primary  
1061 GFAP-positive branches were counted in the molecular layer of the hippocampus. 46 and 41

1062 cells were analyzed for wildtype and knockout, respectively. Numbers of replicates were 4 for  
1063 the control and 3 for the BT-IgSF knockout. Nested t-test.

1064

## 1065 **Figure 6**

1066 **Expression of BT-IgSF on ependymal cells and impaired localization of connexin43 on**  
1067 **ependymal cells in the absence of BT-IgSF (see Figure 6-1 for BT-IgSF antibody**  
1068 **specificity on ependymal cells).**

1069 A) Expression of BT-IgSF in ependymal cells of the lateral, third ventricle and central canal by  
1070 immunohistochemistry using an antibody to the extracellular domain of BT-IgSF. E15 lateral  
1071 ventricle, scale bar 400  $\mu\text{m}$ ; P7 third ventricle, 50  $\mu\text{m}$ ; central canal of an E12.5 spinal cord,  
1072 transversal section; dorsal is up, scale bar 100  $\mu\text{m}$ . Red, anti-BT-IgSF; blue, DAPI. For  
1073 specificity of the antibody sections of BT-IgSF knockout tissue are shown.

1074 B) Higher magnification of the ependymal cell layer showing expression of BT-IgSF at lateral  
1075 and basal sides of ependymal cells in the lateral ventricle of an adult wildtype mouse. Co-  
1076 localization of BT-IgSF and GFAP in the ependyma is shown. Ventricle and the apical side of  
1077 the ependymal cells (indicated by arrow heads) are at the bottom of the image. Scale bar, 20  
1078  $\mu\text{m}$ .

1079 C) BT-IgSF is not or only weakly found at the choroid plexus in contrast to the related CAR.  
1080 Coronal sections from regions of the lateral ventricle from a 19-week-old mouse were stained  
1081 with rabbit antibodies to BT-IgSF (Rb95) or to CAR (Rb80) and DAPI.

1082 D) Clustering of connexin43 on ependymal cells of the lateral ventricle from adult wildtype and  
1083 BT-IgSF knockout mice. Ventricle is at the top of the images. Arrow heads indicate large  
1084 connexin43 cluster. Scale bar, 20  $\mu\text{m}$ .

1085 E - G) Quantification of the number of connexin43 spots, size and distribution of number versus  
1086 size as described for astrocytes. Control,  $283.5 \pm 58.8$ ; BT-IgSF<sup>-/-</sup>,  $132.9 \pm 145.8$  (mean  $\pm$  SD)  
1087 spots from 10 view fields (63x objective) from three animals per genotype. Nested t-test.

1088

1089 **Figure 7**

1090 **Connexin36 localization on neurons is not impaired in the absence of BT-IgSF**

1091 A - D) Specificity of antibodies to connexin36 in Western blots using crude membrane fractions  
1092 from wildtype and connexin36-deficient P10 brain tissues. 12 µg of protein was loaded per  
1093 lane. In A) mAb to connexin36 (sc-398063), in B) mAb to connexin36 (8F6.2), in C) rabbit to  
1094 connexin36 (364600) and in D) rabbit antibody to connexin36 generated in this study (amino  
1095 acid residues 99 to 197) are shown. Satisfactory specificity could only be demonstrated for  
1096 antibody shown in D). A 34 kD protein (arrow heads) was specifically detected in wildtype but  
1097 not in connexin36-deficient tissues. However, a prominent unspecific band at 52 kD was  
1098 detected in both genotypes.

1099 E) Specificity of rabbit antibody to connexin36 (residues 99 to 197) in sagittal sections of P10  
1100 superior colliculus from wildtype and connexin36-deficient mice. Nf, neurofilament.

1101 F) RNAscope demonstrating neuronal expression of BT-IgSF in sagittal sections from P10  
1102 superior colliculus.

1103 G to H) Localization and clustering of connexin36 is not altered in P10 sagittal sections of the  
1104 midbrain in the absence of BT-IgSF. Scale bar, 20µm. Nf, neurofilament. The number of  
1105 connexin36 spots in the midbrain were counted in 3 cryo-sections of 4 animals of each  
1106 genotype. In both cases 2500 µm<sup>2</sup> were analyzed by image J software for each section. Nested  
1107 t-test.

1108 I to K) Connexin36 protein is not altered in the absence of BT-IgSF. Hindbrain (I) and midbrain  
1109 (J), control n=3; knockout, n=4. Mann-Whitney test.

1110

1111  
 1112  
 1113  
 1114

**Table 1: Antibodies for immunohistochemistry, immunocytochemistry and for Western blotting**

Antibody	IHC and ICC	Western blots	Source
mAb $\gamma$ -adaplin RRID:AB_397768	1 $\mu$ g/ml		BD Transduction Laboratories #610385
Rabbit anti-mBT-IgSF-Fc (Rb95 or Rb96) IgG	1-3 $\mu$ g/ml	1 $\mu$ g/ml	Pelz et al., 2017
Rabbit anti-mCAR	1 $\mu$ g/ml		Patzke et al., 2010
mAb anti-connexin43 RRID:AB_397473	1 $\mu$ g/ml		BD Transduction Laboratories, #610061
Rabbit anti-connexin43 RRID:AB_2294590	1:200	1:1000	Cell signaling, #3512
Rabbit anti-connexin30 RRID:AB_2533979	1 $\mu$ g/ml	0.5 $\mu$ g/ml	Invitrogen #71-2200
Rabbit anti-connexin36 RRID:AB_2533260		1 $\mu$ g/ml	Zymed/Invitrogen 36-4600
mAb connexin36 (H9)		1 $\mu$ g/ml	Santa Cruz sc-398063
Rabbit anti-m-connexin36 (RbB5)	0.5 $\mu$ g/ml	0.5 $\mu$ g/ml	This study
mAb 2H3 anti-neurofilament RRID:AB_531793	7.5 $\mu$ g/ml		mAb 2H3 Developmental Hybridoma Bank
mAb 8F6.2 connexin35/36 RRID:AB_94632		1 $\mu$ g/ml	Millipore MAB3045
mAb ZO-1 RRID:AB_2533147	1:200		Invitrogen #339100
Guinea pig anti-GFAP RRID:AB_10641162	1:500	1:1000	Synaptic Systems#173004
Goat anti-GFAP RID:AB_641021	1:200	1:1000	Santa Cruz #sc-6170
Rabbit anti-GFAP RRID:AB_10013382	1:1000		Dako Z0334
mAb GM130 RRID:AB_398142	1 $\mu$ g/ml		BD Transduction Laboratories #610823
mAb LAMP-1 (1D4B)	1 $\mu$ g/ml		Santa Cruz ,sc-19992

RRID:AB_2134495			
mAb anti-MAP2a/b (clone AP20)	1:500	1:1000	Dianova#DLN-08578
Rabbit anti-ZO-1 RRID:AB_2533456	1:100		Invitrogen #40-2200
mAb anti-GAPDH (1D4) RRID:AB_10077627		0.5 µg/ml	Novus Biologicals, #NB300-221
mAb anti-Clathrin (heavy chain) RRID:AB_397865		1:1000	BD Transduction Laboratories #610499
Goat anti-Rabbit- Cy3	1:400 – 1:1000		Dianova
Goat anti-Mouse- Alexa488	1:400 – 1:1000		Molecular Probes
Rabbit anti-Goat- Alexa488	1:500 – 1:1000		Dianova
Goat anti-Rabbit- HRP		1:20 000	Dianova
Goat anti-Mouse- HRP		1:20 000	Dianova

1115  
1116

eNeuro Accepted Manuscript




Figure 1

eNeuro Accepted Manuscript

eNeuro Accepted Manuscript




Figure 2




Figure 3






Figure 4




Figure 5




Figure 6




Figure 7